Drug intelligence / Profile preview

HER3 shRNA

Development stage
Preclinical
Modality
Viral-delivered RNAi → In Vivo RNAi → Gene Silencing → Gene Therapies, RNA Therapeutics → Nucleic Acid Therapeutics
Administration
Intravenous, Intratumoral, Intraperitoneal, Intrathecal
01

Overview

HER3 shRNA is a short hairpin RNA (shRNA) designed to silence the expression of the Human Epidermal Growth Factor Receptor 3 (HER3, also known as ERBB3). By utilizing the RNA interference (RNAi) pathway, the shRNA sequence—often delivered via viral vectors such as pLKO.1—targets HER3 mRNA for degradation, leading to a significant reduction in HER3 protein levels. In preclinical research, particularly in colorectal cancer models, HER3 knockdown has been shown to impede anchorage-independent growth and modulate the HER3-EREG signaling axis, which is associated with disease aggression and poor prognosis. This modality represents a targeted approach to inhibiting HER-family signaling in tumors that may be resistant to traditional EGFR-targeted therapies.

Other names
ERBB3 shRNAERBB-3 shRNAERBB 3 shRNAHER3 short hairpin RNAHER-3 short hairpin RNAHER 3 short hairpin RNAshRNA targeting HER3
02

Targets

Innate immune RNA sensorsERBB3 (Erb-b2 receptor tyrosine kinase 3)

Beyond the preview

Go deeper on HER3 shRNA.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on HER3 shRNA.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call